openPR Logo
Press release

Huateng Pharma Expands CDMO Services in Veterinary APIs, Pharmaceutical Intermediates, Cosmetic Ingredients, and Specialty Chemicals

08-28-2024 08:37 AM CET | Chemicals & Materials

Press release from: Hunan Huateng Pharmaceutical Co., Ltd.

Huateng Pharma, a leading Contract Development and Manufacturing Organization (CDMO), is proud to announce the expansion of its specialized services in Veterinary APIs, Pharmaceutical Intermediates, Cosmetic Ingredients, and Specialty & Fine Chemicals. With a focus on innovation, quality, and customer satisfaction, Huateng Pharma continues to set new benchmarks in the pharmaceutical industry.
Cutting-Edge R&D and Manufacturing Capabilities
Huateng Pharma has significantly invested in its infrastructure to ensure it meets the evolving needs of its clients. The company's 5,000 square meter R&D center is equipped with nearly 100 high-end analytical and testing instruments, including advanced automatic reaction equipment, enabling precise and efficient development processes. This facility allows Huateng Pharma to offer custom synthesis, process development, and analytical services tailored to specific client requirements.
The company's manufacturing prowess is supported by a 34,000 square meter production facility, which includes four modern multi-functional production workshops. These workshops are designed to accommodate a wide range of production needs, from small-scale clinical batches to large-scale commercial manufacturing. The facility adheres to the highest industry standards, featuring 100,000-grade dust-free clean rooms, a GMP-standard production environment, and over 800 advanced facilities and management systems. This ensures that all products are manufactured to the highest levels of quality and compliance.
Commitment to Quality and Compliance
Quality is at the core of Huateng Pharma's operations. The company is committed to maintaining rigorous quality control measures across all stages of production. From raw material procurement to final product testing, every step is carefully monitored to ensure that the highest standards of safety, efficacy, and purity are met. Huateng Pharma's facilities are regularly audited and certified by global regulatory authorities, ensuring compliance with international standards.
Expanding Global Reach and Building Partnerships
Huateng Pharma's expansion is not limited to infrastructure alone. The company is also focused on building strategic partnerships and expanding its global footprint. By leveraging its comprehensive CDMO services, Huateng Pharma aims to become a trusted partner for pharmaceutical companies worldwide. Whether it's developing new veterinary treatments, enhancing cosmetic formulations, or advancing specialty chemicals, Huateng Pharma is dedicated to supporting its clients' success.
Sonia Lee, Business Development Manager at Huateng Pharma, emphasized the company's commitment to collaboration. "At Huateng Pharma, we believe that the key to success lies in strong partnerships. We are eager to work closely with our customers to bring innovative solutions to market, and we are committed to providing the highest levels of service and support," said Lee.
Join Us at CPHI Milan
Huateng Pharma will be showcasing its expanded CDMO services at CPHI Milan, one of the most prestigious events in the pharmaceutical industry, taking place from October 14-16, 2024. Visitors are encouraged to stop by Booth 3F81 to explore Huateng Pharma's offerings, discuss potential collaborations, and meet with Sonia Lee and the business development team.
Attendees will have the opportunity to learn more about Huateng Pharma's capabilities in custom synthesis, process optimization, and large-scale production, as well as its commitment to quality and regulatory compliance. The event will also provide a platform to discuss industry trends and explore how Huateng Pharma can support the future needs of its clients.
For further information, please contact:
Huateng Pharma
Email: sales@huatengusa.com
Website: us.huatengsci.com

Website: https://us.huatengsci.com
Email: sales@huatengusa.com
Zip code: 410205
Telephone: +86 731 89916275
Fax: + 86 731-82251112 EXT 818
Headoffice: Building E1, Lugu Corporation Plaza, High-Tech Industrial Development Zone, Changsha City, Hunan Province, P.R.China

Huateng Pharma is a leading CDMO providing comprehensive services in the fields of Veterinary APIs, Pharmaceutical Intermediates, Cosmetic Ingredients, and Specialty & Fine Chemicals. With cutting-edge R&D and manufacturing facilities, Huateng Pharma is committed to delivering high-quality products and solutions to its global partners. The company's dedication to innovation, quality, and customer satisfaction has earned it a reputation as a trusted partner in the pharmaceutical industry.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Huateng Pharma Expands CDMO Services in Veterinary APIs, Pharmaceutical Intermediates, Cosmetic Ingredients, and Specialty Chemicals here

News-ID: 3636888 • Views:

More Releases from Hunan Huateng Pharmaceutical Co., Ltd.

Huateng Pharma Introduces New Cosmetic Actives to Meet Growing Demand for High-P …
Huateng Pharma, a global leader in specialty chemicals, has expanded its product portfolio to include a new line of high-quality cosmetic ingredients. The launch addresses the increasing demand for effective, safe, and readily available actives for modern skincare and personal care formulations. The new offerings are now available for immediate delivery and include several key ingredients: Diethylamino Hydroxybenzoyl Hexyl Benzoate (CAS 302776-68-7): A REACH-registered UVA filter that provides broad-spectrum sun protection. This
Huateng Pharma Highlights the Pharmaceutical Potential of N-Benzylhydroxylamine …
Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical developers worldwide. This compound has gained attention for its multifunctional properties and critical role in drug discovery and development. N-Benzylhydroxylamine Hydrochloride features a unique nitrogen-oxygen (N-O) functional group, which enables its wide-ranging applications in medicinal chemistry, including: Metal Chelation for Iron Overload Disorders: Its
Huateng Pharma to Showcase Extensive PEG Derivatives and CDMO Capabilities at CPHI Japan 2025
Huateng Pharma to Showcase Extensive PEG Derivatives and CDMO Capabilities at CP …
Changsha, China - 18 March 2025 - Hunan Huateng Pharmaceutical Co., Ltd., a global leader in PEG derivatives and CDMO services for APIs and intermediates, is pleased to announce its participation in CPHI Japan 2025. The company will exhibit its comprehensive product lines and cutting-edge capabilities at Booth No. 4X-06, located at Tokyo Big Sight, Tokyo, Japan, from April 9th to 11th, 2025. Huateng Pharma is dedicated to providing robust support
Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval
Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval
Changsha, China - Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma's dedication to meeting the highest regulatory standards and further strengthens its commitment to supporting

All 4 Releases


More Releases for Pharma

Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031. The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the